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Abstract
Recent epigenetic association studies have identified a new gene, ANK1, in the pathogene-
sis of Alzheimer’s disease (AD). Although strong associations were observed, brain homog-
enates were used to generate the data, introducing complications because of the range of
cell types analyzed. In order to address the issue of cellular heterogeneity in homogenate
samples we isolated microglial, astrocytes and neurons by laser capture microdissection
from CA1 of hippocampus in the same individuals with a clinical and pathological diagnosis
of AD and matched control cases. Using this unique RNAseq data set, we show that in the
hippocampus, ANK1 is significantly (p<0.0001) up-regulated 4-fold in AD microglia, but not
in neurons or astrocytes from the same individuals. These data provide evidence that micro-
glia are the source of ANK1 differential expression previously identified in homogenate sam-
ples in AD.
Introduction
Alzheimer’s disease (AD) is a multi-factorial neurological disorder classically characterized by
amyloid plaques[1] and neurofibrillary tangles[2]. AD also features many signs of chronic
inflammation[3, 4]. Microglia, resident immune cells within the central nervous system, are
key regulators of the inflammatory cascade[5], which has been proposed as an early event in
AD[6, 7]. It has been known for decades that microglia have the ability to release neuro-toxic
inflammatory factors, which have prompted hundreds of studies to address a causal mecha-
nism[8]. Although may genetic association studies have identified potential glial-associated
alterations (e.g. TREM2) [9], none have been absolute in predicting disease. Recent studies
have reached beyond genetic variation, but instead looked towards epigenetic changes as a
mechanism by which environment can interact with genome.
As such, recent epigenetic-wide association studies (EWAS) have identified a class of genes
associated with AD risk. Ankyrin repeat domain-containing proteins are plasma bound
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membrane proteins, which modulate interactions between cytoskeletal and membrane pro-
teins[10]. A specific ankyrin repeat domain-containing protein, ANK1, has been a source of
great interest in the field of AD[11–13] and type 2 diabetes[14, 15], a recognized risk factor for
AD[16]. Two independent EWAS have identified methylation changes in the ANK1 gene that
are associated with AD[11, 12]. These studies indicate that epigenetic mechanisms (e.g. DNA
methylation) and the rise of age-dependent inflammatory conditions are major risk factors for
AD, and ANK1may be the link between the two[12]. However, these studies which draw atten-
tion to ANK1 as a potentially critical molecule in the pathophysiology of AD were conducted
on homogenates brain samples, which leaves unresolved the identity of the cells impacted by
DNA hypermethylation in AD. Here, we provide evidence that microglia are the source of
ANK1 differential expression in the AD brain.
Methods
Ethics statement
Written informed consent for autopsy was obtained in compliance with institutional guide-
lines of Banner Sun Health Research Institute. Banner Sun Health Research Institute Review
Board approved this study including recruitment, enrollment, and autopsy procedures. Indi-
vidual person(s) and their respective next-of-kin consented to brain autopsy for the purpose of
research analysis as participants in the Banner Sun Health Research Institute brain and body
donation program. The human brain tissue used in this manuscript was from routine existing
autopsies, which fully qualifies for 4C exemption by NIH guidelines. In addition, samples were
analyzed anonymously (e.g. sample numbers) throughout the experimental process.
Laser capture microdissection of microglia and RNA sequencing
Tissue collection. Frozen unfixed tissue containing CA1 of hippocampus were collected
at Sun Health Research Institute (Alzheimer’s Disease Centers) from clinically and neuro-
pathologically classified late-onset AD-afflicted individuals with a mean age of 74.6 ± 6.8 years;
healthy elderly controls with a mean age of 73.6 ± 6 years; and Parkinson’s disease cases with a
mean age of 74.6 ± 15.6 years. Detailed sample information, including post mortem interval
(PMI) can be found in Table 1.
Immunohistochemistry for laser capture. Frozen brain tissue sections (10μm) were
mounted onto PEN slides and fixed in ice cold acetone/ethanol for 10 min on ice. Sections
were washed in ice cold 1X Phosphate buffered saline (PBS), blocked in 1% hydrogen peroxide
for 2 minutes, followed by 3 quick submersions in ice cold 1X PBS. Sections were then placed
in 1:500 dilution of primary antibody in 1X PBS supplemented with 50U RNAseOUT (Invitro-
gen) for 10 minutes at room temperature. After the incubation, sections were washed three
times in 1X PBS and incubated in avidin(1:300)-biotin(1:300) complex (Vector) in 1X PBS for
10 minutes at room temperature (RT). Sections were washed three times in 50mM Tris buffer
and immersed in 3.3’-diaminobenzidine (DAB) solution (9.3 ml 50mM Tris; 200 μl DAB
(5mg/ml); 500 μl saturated nickel; and 4 μl of 1% H202) for 5 minutes, followed by two quick
rinses in 50mM Tris to stop the reaction.
Laser capture of LN3-positive microglia. LN3 antibody reacts with MHCII microglia.
These microglia are said to be antigen presenting (e.g. activated, M1 phase, but not phagocytic
M2). Immediately after detection of LN3-immunoreactivity, sections were dipped in 100%
ethanol and loaded onto a Leica AS-LMD laser capture microscope. After objective calibration,
600 LN3-positive cells were captured using 20X magnification. Individual microglial cells were
cut and dropped into an inverted microcentrifuge cap containing 50μl buffer RLT (RNeasy
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Micro Kit—Qiagen) and 1% β-Mercaptoethanol. Detailed schematic of laser capture can be
seen in (S1 Fig).
Laser capture of GFAP-positive Astrocytes. Glial fibrillary acidic protein is an intermedi-
ate filament protein that is expressed by astrocytes. Immediately after detection of GFAP-immu-
noreactivity, sections were dipped in 100% ethanol and loaded onto a Leica AS-LMD laser
capture microscope. After objective calibration, 600 GFAP-positive cells were captured using
20X magnification. Individual astrocytes were cut and dropped into an inverted microcentrifuge
cap containing 50 μl buffer RLT (RNeasy Micro Kit—Qiagen) and 1% β-Mercaptoethanol.
Laser capture of pyramidal neurons. Brain sections were stained with 1% neutral red
(Fisher Scientific); pyramidal neurons were identified by their characteristic size, shape, and
location. Immediately after staining sections were dipped in 100% ethanol and loaded onto a
Leica AS-LMD laser capture microscope. After objective calibration, 300 pyramidal neurons
were captured using 20X magnification. Individual neurons were cut and dropped into an
inverted microcentrifuge cap containing 50 μl buffer RLT (RNeasy Micro Kit—Qiagen) and
1% β-Mercaptoethanol.
RNAseq library preparation. Total RNA was used to generate whole transcriptome
libraries for RNA sequencing. Using the Nugen Ovation RNA-Seq System v2, total RNA was
used to generate double stranded cDNA, which is subsequently amplified using Nugen’s SPIA
linear amplification process. Amplified products were cleaned using the QIAquick PCR Purifi-
cation Kit (Qiagen) and quantitated using Quant-iT Picogreen (Invitrogen). 1 μg of amplified
cDNA was fragmented on the Covaris E210 to a target size of 300bp. Kapa Biosystems’ Library
Preparation Kit and Illumina adapters and sequencing primers were used for preparing librar-
ies from amplified cDNA. Final libraries were quantified using the Agilent Bioanalyzer and
Life Technologies/Invitrogen Qubit.
Paired end sequencing. Libraries with a 1% phiX spike-in were used to generate clusters
on HiSeq Paired End v3 flowcells on the Illumina cBot using Illumina’s TruSeq PE Cluster Kit
Table 1. Clinical and pathological patient demographics.
Gender Clinical and Pathological Diagnosis Expired Age PMI APOE Braak
NFT Stage
RIN Values Whole Tissue
Male ND 93 3 3/3 I 6.9
Male ND 73 2.5 2/3 II 7
Male ND 89 5.5 3/3 II 7.8
Male ND 79 3 3/3 II 7
Male ND 53 3.66 3/3 I 7.1
Male ND 61 2.33 3/3 I 7
Male AD 75 2 3/4 V 7.3
Male AD 70 2.33 3/4 V 6.7
Male AD 76 4 4/4 V 7.1
Male AD 64 2.33 3/3 VI 7.2
Male AD 82 2.95 3/3 V 7.3
Male AD 75 3.83 3/4 V 7.1
Male PD 69 2.25 3/4 II 7
Male PD 72 3.5 2/3 II 7.2
Male PD 70 2.33 3/3 II 7.8
Male PD 69 3.37 3/3 II 7.5
Male PD 78 2.75 3/3 II 7.1
Male PD 86 3 3/3 III 6.9
https://doi.org/10.1371/journal.pone.0177814.t001
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v3. Clustered flowcells were sequenced by synthesis on the Illumina HiSeq 2000 using paired-
end technology and Illumina’s 200 cycle TruSeq SBS Kit, extending to 83 bp for each of two
reads and a 7bp index read. Approximately 250–300 Gigabases (Gb) of reads were generated
per flowcell based on Illumina’s published throughput. Quality Control (QC) Steps: During
library preparation, electrophoretically separated fragmented cDNA was analyzed on a TAE
gel to verify fragmentation. Final libraries were run on a Bioanalyzer to verify sizes and quanti-
tate libraries prior to sequencing. During and following sequencing, we evaluated the total
amount of Q30 data generated per library, total number of reads generated, and the total num-
ber of mappable reads.
Data analysis. Following completion of sequencing, we initiated an automated in-house
pipeline for next generation sequencing (NGS) analysis through our laboratory database. From
within this database, we have automated the generation of pipeline configuration files for NGS
data processing, which generates pipeline analysis without manual intervention. Our analysis
pipeline produces standard platform independent formats and a summary of sequencing analy-
sis. Each software tool, including those internally developed, has been validated on multiple
simulated and model data sets to characterize each tool’s strengths and biases. At each step
within the pipeline, statistics files were created to ensure that all processes have completed and
files are uncorrupted. Early within the pipeline, several additional checks are invoked including
estimates of overall coverage on a library, evenness of a library, quality of bases, and contamina-
tion checks. This pipeline is built around (1) standardized file formats; (2) multiple quality con-
trol checks; (3) automated processing; (4) scheduled releases of sequence data, sequencing
alignments, and variant calls; and (5) centralized primary data processing. Reads first went
through a series of QC steps, quantifying for biases at any given base, and were then parsed by
barcode into independent FASTQ files. FASTQ alignments were aligned with TopHat [17, 18].
Alignment produced single BAM files containing both aligned and unaligned data.
Statistical analysis. TopHat and Cufflinks were used to assemble reads into transcripts,
and HTSeq was used to generate counts data from Cufflinks’ output. DESeq2 calculates nor-
malized read counts for each gene/transcript and uses a generalized linear model to evaluate
differential expression between sample groups while accounting for biological variance.
DESeq2 uses a Wald statistic as a measure of significance, and the Benjamini and Hochberg
False Discovery Rate (FDR) were used for multiple testing corrections. Genes with an adjusted,
or corrected, P< 0.05 were evaluated. Variability in the number of reads was accounted for
during normalization of read counts. Therefore, we collected data from samples which gave us
at least 50 million reads; samples with lower than 50 million reads were omitted. Intronic
sequences were analyzed using an unbiased approach to evaluate changes in expression of all
RNAs but not small RNAs. Final libraries were run through the Bioanalyzer to verify sizes, and
to quantitate libraries prior to sequencing. During and following sequencing, we evaluated the
total amount of Q30 data generated per library, total number of reads generated, and the total
number of mappable reads. RNA sequencing data can be accessed at National Institute on
Aging Genetics of Alzheimer’s Disease Data Storage Site, accession number NG00057.
Hippocampal homogenates and affymetrix arrays
Tissue collection. As previously published[19, 20], frozen unfixed tissue was obtained
from 26 non-AD controls (age 69–99 years), and 18 Alzheimer’s disease cases (age 74–95
years) (from seven nationally recognized brain banks. Refer to references[19, 20] for detailed
sample information. Total RNA was extracted from hippocampus as described previously19.
Forty-four hippocampal tissue samples were individually hybridized to Affymetrix HgU133
plus 2.0 arrays.
ANK1 is up-regulated in laser captured microglia in Alzheimer’s brain
PLOS ONE | https://doi.org/10.1371/journal.pone.0177814 July 12, 2017 4 / 11
We preferentially selected those probe sets that were most specific, such that they were
annotated with the smallest number of Ensembl gene IDs. After applying this criterion, if there
remained multiple probes for any one gene, we excluded those probe sets expected to hybridize
with targets in a non-specific fashion (i.e., those with “_x_” in the Affymetrix identifier). If
there still remained multiple probe sets for a given gene, we took the mean of both probe sets.
Statistical analysis. Select genes were investigated for statistical significance (p< 0.01) in
aging/ND (n = 26, age 69–99, mean age 82 ± 9.8 years) versus AD (n = 26, age 69–99, mean
age 82 ± 9.8 years All genes that did not meet the 50% present call threshold were removed by
Genespring G 7.3.1 Expression Analysis software. A two-tailed paired t-test, assuming equal
variance (using multiple testing corrections, by Benjamini and Hochberg False Discovery
Rate), was applied to locate genes that were significant in differentiating expression between
AD and ND cases.
Results
ANK1 expression levels are increased in AD microglia, but not in AD
Astrocytes or AD neurons from the same individuals
Current data shows a strong significant hypermethylation of ANK1 in AD cortex [11, 12],
however no data exist on which classes of cell(s) are associated with these changes. In order to
connect the observed changes in ANK1 to a specific cell type, we mined our previously pub-
lished homogenate mRNA data [19, 20], and compared these findings to RNA sequencing
data we generated from microglia, astrocytes and neurons from the same subjects.
In order to parallel previously published EWAS studies, ANK1mRNA expression was ini-
tially investigated in homogenate samples derived from human hippocampus. No significant
difference in ANK1 expression was detected between AD and control samples (p = .323) (Fig 1).
These data suggest that the limbic (studied here) and sub-cortical regions (studied in EWAS)
may be different in terms of ANK1 expression, that the number of cells analyzed in homoge-
nates is too large to detect subtle differences in single cell populations, splice variants, or that
separate cell populations may demonstrate overlapping and wide variance in ANK1 expression.
In order to address the effect of cellular heterogeneity, data from laser-captured microglia,
astrocytes and neurons were analyzed. Analogous to homogenate samples, no significant dif-
ference in ANK1 expression was found between control neurons and AD neurons (p>.1), or
control astrocytes and AD astrocytes (p>.1) (Fig 1). In stark contrast, AD microglia from the
same individuals, in the same brain region revealed a significant (p<0.01) 4.1-fold increase in
ANK1 expression compared to microglia isolated from control brain samples. Quantitation of
these findings were replicated using real-time PCR (S2 Fig). These findings suggest that the
insignificant change in homogenates between AD and control brain concealed highly signifi-
cant alterations in ANK1 expression in microglia in AD. Given that neuronal cells express
higher ANK1 levels compared to microglial samples (Base-Mean 9 vs. 2 respectively) may indi-
cate that the ANK1 gene may have a significant role in neuronal function although no disease
associations can be made. These findings show that expression profiling of laser captured cells
is required to clarify data from homogenate studies.
In order to determine disease specificity, laser captured CA1 microglia from Parkinson’s
cases were also analyzed. Similar differential expression patterns were identified in PD micro-
glia for two of the eight genes analyzed (ANK1, and ANKLE2) (Fig 2D). These data show that
unlike homogenate and LCM neurons, ANK1 is significantly up-regulated in both AD and PD
microglia. These data suggest that alterations in ANK1, at least in microglia, may not be disease
specific, but rather a response, or phenotype associated with neurodegeneration. Interestingly,
when other brain regions were analyzed (e.g. substantia nigra), PD microglia showed a
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significant 2-fold increase in ANK1 expression (S1 Table), providing further evidence for the
notion that ANK1 may be involved in, or associated with, the process of neurodegeneration,
more specifically, neuroinflammation.
Analysis of ankyrin repeat-domain genes
In order to determine if other genes containing ankyrin repeat domains were selectively
affected by disease, we analyzed all the significantly altered ANK1-like genes in homogenates,
LCM neurons, astrocytes and microglia.
Homogenate samples. Expression data generated from hippocampal homogenates
revealed only two significant changes in genes containing ankyrin repeat domains (ANKRD16
p =<0.014) and ANKLE2(p =< .0132) (Fig 2A).
Laser captured neurons. Expression data from CA1 neurons show significant changes in
fourteen genes containing Ankryin repeat domains (Fig 2B). Thirteen of the fourteen genes
were downregulated; the largest fold-change (-2.3) was identified in ANKRD18A (p = 0.0028),
a gene not identified as significantly altered in homogenates, or in LCM glia. The only Ankyrin
repeat gene significantly up-regulated was ANKRD34A (p = 0.021) (Fig 2B).
Laser captured microglia. Expression data from laser captured microglia isolated from
CA1 of hippocampus show similar expression changes in ANKLE2 (p =< .001) compared to
homogenates (see Fig 2A compared to Fig 2C).
Laser capture astrocytes. Expression data from laser captured astrocytes isolated from
CA1 of hippocampus from the same individuals showed no overlap in any of the aforementioned
ankyrin repeat genes identified in neurons or microglia. Interestingly, three unique ankyrin
repeat genes were identified in astrocytes. Significant (p< .05) upregulation of ANKRD36
(5-fold increase), ANKRD52 (4.3-fold increase), and ANKRD18CP (4.6-fold increase) were
observed. A detailed list of all the Ankyrin repeat genes can be found on S1 Table.
Differential expression analysis in EWAS related genes
In addition to the differential methylation changes in the ANK1 gene in AD [11], recent
EWAS studies also identified a number of other loci as being differentially methylated in
Fig 1. ANK1 mRNA expression levels in hippocampal homogenates, AD CA1 pyramidal neurons AD
CA1 astrocytes and AD CA1 microglia. Bar graph depicts log2 fold change, comparing AD vs. age matched
normal controls. No significant difference was detected in homogenates, AD neurons, or AD astrocytes. In
stark contrast, a significant four-fold increase (p<0.001) was observed in AD microglia.
https://doi.org/10.1371/journal.pone.0177814.g001
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disease (ABCA7,BIN1, CDH23, DIP2A, RHBDF2, RPL13, RNF34, SERPINF1 and SERPINF2).
Of the nine genes identified by De Jager and colleagues, six were also identified in LCM CA1
neurons (CDH23, RPL13, RNF34, SERPINF1, ABCA7, and SERPINF1), but only one was found
to be significantly differentially expressed Bin 1 (p =<0.021), (Fig 3).
In microglia, one gene, SERPINF2, had a significant (p =<0.001) increase in expression in
AD (p =<0.001) compared to control (Fig 3). This same gene was not differentially expressed
in AD homogenates or AD neurons. These data suggest that homogenates are inadequate pre-
dictors of global gene expression changes. In fact, homogenate samples appear to mask impor-
tant changes in single cell classes.
Discussion
Recent studies of human brain homogenates have identified hypermethylation of the ANK1
gene in Alzheimer’s disease[11, 12]. Unfortunately, the interpretation of these data is obscured
since brain homogenates produce data that result from many different classes of cells in many
different disease states. These authors (DeJager et al., 2014; Lunnon 2014) acknowledge this
Fig 2. Significant, Log2 fold change(s) in genes containing ankyrin repeat domains in AD hippocampal homogenates, AD CA1 pyramidal
neurons, AD CA1 astrocytes and AD CA1 microglia. A) Significantly (p < .05) altered Ankyrin repeat containing genes in hippocampal homogenates in
AD compared to ND. B) Significantly altered (p < .05) Ankyrin repeat containing genes in LCM neurons and glial cells (C). D) average log2 mRNA fold
difference in ankyrin repeat genes in PD microglia from CA1 of the hippocampus compared to the same matched control subjects used in AD comparisons.
LCM neurons, astrocytes and microglia were derived from the same human subjects. Detailed expression changes can be found in S1 Fig.
https://doi.org/10.1371/journal.pone.0177814.g002
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issue in their homogenate data, but speculate that their ANK1 findings may be related to acti-
vation of microglia through association with PTK2B, a gene that is associated with many
microglial processes[21–28]. In order to address the issue of cellular heterogeneity, we isolated
microglial, astrocytes, and neurons in the same individuals by laser capture microdissection
from CA1 of hippocampus in AD, and in normal control cases. Using these data sets, we deter-
mined that ANK1 expression is up-regulated 4-fold in AD microglia, but not in pyramidal
neurons or astrocytes from the same individuals.
We note that, although the conventional association between DNA methylation and gene
expression is that hypermethylation is repressive, we found increased expression in ANK1 –the
gene that prior studies found to be hypermethylated. We speculate that this apparent inconsis-
tency may be attributable to the location (e.g. intragenic regions) identified in the EWAS
study, however other explanations are possible. For example, the data generated in EWAS
studies was derived from bisulfite-treated DNA, therefore the signal is the sum of DNA meth-
ylation marks including hypermethylation, which may have different effects on transcription.
As such, recent studies have shown that an increase in methylation within intragenic regions
results in an increase in gene expression and gene activation[29–31].
The lack of altered ANK1 expression in hippocampal homogenates compared to findings of
increased DNA methylation in other studies[11, 12] may be attributed to several factors: 1) the
different brain regions studied, for example neocortical vs. limbic in our data; 2) the complexi-
ties of the relationship between DNA methylation and gene expression; 3) dilution effects of
homogenates and 4) differential splicing of the gene. In addition, the lack of altered ANK1
expression in hippocampal homogenates in our data, compared to our finding of increased
expression of ANK1 in microglia from a hippocampal sub-region, may be attributed to dilu-
tion effects of homogenates.
Fig 3. mRNA expression analysis of EWAS-related genes in AD CA1 pyramidal neurons AD CA1
astrocytes and AD CA1 microglia. Only two of the seven identified transcripts in the EWAS study were
significantly differentially expressed, BIN1 in AD neurons and SERPINF2 in AD microglia. * indicates p < .05.
https://doi.org/10.1371/journal.pone.0177814.g003
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These data show that unlike homogenate and LCM neurons, ANK1 is significantly up-regu-
lated in both AD and PD microglia, suggesting that alterations in ANK1, at least in microglia,
may not be disease specific, but rather a response to a common pathway affected in neurode-
generation. (e.g. inflammation, or oxidative stress). The role of increased expression of ANK1
in Alzheimer’s microglia remains to be determined; but more importantly, these findings
emphasize that expression profiling of defined classes of cells is required to clarify data from
homogenate studies.
Supporting information
S1 Table. Detailed description, Base Mean expression, log2 fold change, and associated p-
value of every gene analyzed in this study.
(PDF)
S1 Fig. Schematic of laser capture microdissection on hippocampal tissue sections (A) Hippo-
campal sections were immunoreacted using an antibody to LN3 (B), and ~600 LN3 positive
microglia cells were captured (C). Individual microglial cells were cut and dropped into an
inverted microcentrifuge cap (D) and processed for RNA sequencing or qPCR.
(PDF)
S2 Fig. Quantitative RT-PCR of ANK1 gene expression levels in AD CA1 laser capture
microglia (green tracer), compared to NC (blue tracers). Note, AD microglial- ANK1
expression levels peak at 25 cycles compared to 30 cycles in NC microglia.
(PDF)
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